A retrospective pooled biomarker study to predict overall survival beyond the TNM system
K. G. Jebsen Colorectal Cancer Research Centre scientists participated with data from patients admitted to Oslo University Hospital in a multicenter study of >7000 stage II and III CRC recently reported in Annals of Oncology, Dienstmann et al., March.
About the study
Incorporation of MSI, BRAFV600E and KRAS mutation status to overall survival models with TNM staging improves the ability to precisely prognosticate in stage II and III CC patients, but only modestly increases prediction accuracy in multivariable models that include clinicopathological features, particularly in chemotherapy-treated patients.
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study
Dienstmann R et al.
Ann Oncol. 2017 Feb 9.
Latest publicationsBrunsell et al. 2019. High concordance and negative prognostic impact of RAS/BRAF/PIK3CA mutations in multiple resected colorectal liver metastases. Clin. Colorectal Cancer [Online ahead of print] Sveen et al. 2019. Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes. Ann. Oncol. 30(11): 1682-1685 Miranda et al. 2019. Cancer stemness, intratumoral heterogeneity, and immune response across cancers. PNAS 116(18): 9020-9029 Burocziova et al. 2019. Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon. Cell Death. Dis. 10(11): 818
Eilertsen et al. 2019. Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. Cancer Lett. [Epub ahead of print] All publications